You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201791 - 201800 of 207712 results
  1. Robust and Efficient Method for Pharmaceutical Freeze Drying in Pre-Filled Syringes

    SBC: PHYSICAL SCIENCES INC.            Topic: NCI

    DESCRIPTION (provided by applicant): The goal of the proposed SBIR program is to develop lyophilizer manufacturing hardware and processing procedures that enable the efficient freeze drying of pharmaceutical product formulations in prefilled syringes. Theuse of prefilled syringes 1) reduces dosing and medication errors, 2) reduces the risk of microbial contamination, 3) improves dosing accuracy, 4 ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Inhibiting PLEKHA7 for mutant KRAS therapy

    SBC: PHusis Therapeutics Inc            Topic: NCI

    DESCRIPTION (provided by applicant): Oncogenic KRAS is found in 25% of patient tumors across many cancer types. Despite extensive effort since its discovery over 30 years ago there is still no effective treatment for KRAS tumors. An estimated 350,000 patients in the US in 2013 will be diagnosed with mutated KRAS in their tumor, and many will die of their disease. Mutated KRAS plays a critical role ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a 3-D multi-planar biopsy system using new ultrasound tomographic

    SBC: Delphinus Medical Technologies, Inc            Topic: NCI

    PROJECT SUMMARY Biopsy capability is an absolute requirement for imaging facilities planning to provide breast cancer screening services. The limitations of mammography have ushered in several other imaging technologies, such as magnetic resonance (MR), positron emission mammography, and breast specific gamma, or molecular breast imaging. However, these are all relatively expensive modalities and ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Development of an Ad5-CEA/Brachyury Vector Approach for Cancer Treatment

    SBC: Etubics Corporation            Topic: NCI

    DESCRIPTION (provided by applicant): With the discovery of new biomarkers associated with tumor development, many of these tumor-associated antigens (TAA) are being utilized in immunotherapeutic modalities designed to induce anti-tumor directed cytotoxicimmune responses. It is increasingly clear that not any one of these TAA is sufficient, as a single entity to develop an immunotherapeutic treatm ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Curated copy number variation TCGA database and analytical platform for use in ca

    SBC: BIODISCOVERY, INC            Topic: NCI

    DESCRIPTION (provided by applicant): Cancers selected for the NIH's The Cancer Genome Atlas (TCGA) project have been chosen because of their poor prognosis and overall public health impact. Select tissue samples have been profiled for gene and miRNA expression, promoter methylation, DNA sequence and mutation analysis, as well as copy number variation (CNV), with total expenditures of 275 Mil ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Targeted Theranostics for Metastatic Melanoma

    SBC: RADIOMEDIX, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): The American Cancer Society reports that death rates for melanoma have been rising in the United States for the past 30 years. It is one of the more common cancers in population younger than 30, and the most common cancer in adults ages 25 to 29. One characteristic of metastatic melanoma cells that is recognized as a potential target for new therapies is their ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Intravesical Chitosan IL-12 Therapy in an Orthotopic Mouse Bladder Cancer Model

    SBC: SCION CARDIO-VASCULAR, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): This SBIR project brings together the skills and resources of laboratories at Scion Cardio-Vascular Inc. (Scion C-V), Loma Linda University, and North Carolina State University to advance a new signaling molecule treatment for superficial bladder cancer. This treatment delivers the cytokine Interleukin 12 (IL-12) to the bladder wall using Scion C-V's muco ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Integrated System for FFPE Sample Preparation

    SBC: COVARIS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Many samples taken from individuals and animals are stored by treating them with chemical, formalin, and then encasing them in paraffin or wax; these are called formalin fixed paraffin encased (FFPE) samples. Usually this storage is very good for preserving them for observation under microscopes, but it presents some problems in terms of analysis of their DNA. ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Dampening CAR therapy-induced cytokine storm with anti-GM-CSF antibodies

    SBC: CELDARA MEDICAL, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): The long-term aim of this project is to reduce or eliminate the serious adverse events associated with cellular immunotherapy used to treat cancer. The current impressive efficacy of chimeric antigen receptor (CAR) T cell therapies is often accompanied by a well-known toxicity stemming from the large release of cytokines from activated immune cells, known as a ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. STING-Activating GM-CSF Secreting Allogeneic Pancreas Tumor Cell Vaccine Therapy

    SBC: ADURO BIOTECH            Topic: NCI

    DESCRIPTION (provided by applicant): The incidence of pancreatic adenocarcinoma (PDA) is gt 45,000 cases per year in the US and is increasing. While new chemotherapy regimens such as Abraxane and FOLFIRINOX extend overall survival, none offer the promise of long-term disease-free survival. We submit that immunotherapy can be an effective and durable therapeutic option for PDA. Here we extend both ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government